Validation of the Royal Marsden Hospital prognostic score in patients treated in the phase i clinical trials program at the MD Anderson Cancer Center

Cancer

Volumn 118, Issue 5, 2012, Pages 1422-1428

  Garrido Laguna, Ignacio ^a   Janku, Filip ^a   Vaklavas, Christos ^a   Falchook, Gerald S ^a   Fu, Siqing ^a   Hong, David S ^a   Naing, Aung ^a   Tsimberidou, Apostolia M ^a   Wen, Sijin ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

head and neck cancer; lung cancer; pancreatic cancer; phase 1 trials; prognosis score

Indexed keywords

ALBUMIN; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; ARSENIC; CELL CYCLE INHIBITOR; CURCUMIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; INTERFERON; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICROTUBULE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEOSOME INHIBITOR; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER CENTER; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER SURVIVAL; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FEMALE; FIRST IN HUMAN STUDY; HEAD AND NECK CANCER; HEALTH PROGRAM; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; RETROSPECTIVE STUDY; ROYAL MARSDEN HOSPITAL PROGNOSTIC SCORE; SCORING SYSTEM; SOLID TUMOR; SURVIVAL TIME; VALIDATION PROCESS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CANCER CARE FACILITIES; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROGNOSIS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; TEXAS; TREATMENT OUTCOME;

EID: 84857339127     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26413     Document Type: Article

References (22)

1. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005; 352: 895-904. (Pubitemid 40300298)
2. Kurzrock R, Benjamin RS,. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med. 2005; 352: 930-932. (Pubitemid 40300304)
3. Roberts TG Jr, Goulart BH, Squitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004; 292: 2130-2140. (Pubitemid 39435104)
4. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361: 123-134.
5. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363: 809-819.
6. Han C, Braybrooke JP, Deplanque G, et al. Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer. 2003; 89: 1166-1171. (Pubitemid 37363397)
7. Arkenau HT, Olmos D, Ang JE, et al. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer. 2008; 44: 1536-1540.
8. Arkenau HT, Barriuso J, Olmos D, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol. 2009; 27: 2692-2696.
9. Wheler J, Tsimberidou AM, Hong D, et al. Survival of patients in a phase 1 clinic: the M. D Anderson Cancer Center experience. Cancer. 2009; 115: 1091-1099.
10. Garrido-Laguna I, Janku F, Falchook GS, et al. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last Food and Drug Administration-approved treatment. Clin Cancer Res. 2010; 16: 4031-4037.
11. Vaklavas C, Tsimberidou AM, Wen S, et al. Phase 1 clinical trials in 83 patients with pancreatic cancer: the M. D Anderson Cancer Center experience. Cancer. 2010; 117: 77-85.
12. Janku F, Tsimberidou AM, Wang X, et al. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist. 2011; 16: 327-335.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
14. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
15. Mantel N,. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170.
16. Cox DR,. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 34: 187-220.
17. Jain RK, Lee JJ, Hong D, et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010; 16: 1289-1297.
18. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
19. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009; 361: 1164-1172.
20. Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S,. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer. 2008; 98: 1029-1033. (Pubitemid 351399798)
21. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitor. Mol Cancer Ther. 2011; 10: 558-565.
22. Beadling C, Heinrich MC, Schuff K, Druker BJ, Corless CL,. Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry [abstract]. J Clin Oncol. 2010; 28 (15S). Abstract 10503.